FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Deep Sleep + GH Stack

Sleep Optimizationintermediate

85

상호작용

85
Share
펩타이드

3

일 평균 mcg

5,400

수준

intermediate

추가됨

May 17, 2026

개요

The Deep Sleep + GH Stack is a comprehensive nocturnal optimization protocol that combines sleep induction, circadian rhythm restoration, and GH pulse amplification — targeting all three systems that govern what the body accomplishes during sleep. DSIP (Delta Sleep-Inducing Peptide) increases slow-wave sleep duration and quality. Slow-wave sleep is the stage when growth hormone is secreted, cellular repair occurs, and memories are consolidated. DSIP normalizes sleep architecture rather than forcing sedation — it works with the brain''s natural sleep regulation rather than bypassing it. Epithalon, administered in a 10-day course, targets the deeper circadian regulation governed by the pineal gland. As we age, the pineal''s melatonin production and overall regulatory function decline, disrupting the circadian rhythms that govern when the body performs repair, immune surveillance, and hormonal secretion. Epithalon''s activation of telomerase and pineal function restores more youthful circadian patterns — longer, deeper sleep with more consistent timing. CJC-1295 amplifies the GH pulse that naturally occurs during slow-wave sleep. By administering it in the evening before sleep, users time the CJC-1295-driven GH surge to coincide with the DSIP-enhanced slow-wave sleep period. The result is a significantly larger nocturnal GH secretion event — greater than DSIP or CJC-1295 would produce independently. This stack treats sleep as the metabolic and regenerative event it is, rather than just as rest. It is particularly powerful for anti-aging applications, post-injury recovery, and body composition optimization — all domains where nocturnal GH secretion is a primary driver of outcomes.

용량 프로토콜

DSIP

nightly· subcutaneous

DSIP에 대한 자세한 내용 →

100 mcg

1회 용량당

Epithalon

nightly (10-day course)· subcutaneous

Epithalon에 대한 자세한 내용 →

5,000 mcg

1회 용량당

CJC-1295

nightly· subcutaneous

CJC-1295에 대한 자세한 내용 →

300 mcg

1회 용량당

목표 및 증거

Deep sleep qualityGH optimizationAnti-agingCircadian rhythm restorationRecovery
증거 등급:동물 연구

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.